Figure 2. A schematic illustration of plausible NLRP3 inflammasome-related mechanisms targeted by clinically approved drugs, repurposed to manage COVID-19. Following SARS-CoV-2 interaction with ACE2 receptors, NLRP3 inflammasome is up-regulated to induce immune response against the virus. Overall, the over-activation of NLRP3 amplifies the innate immune response and contributes to cell death by pyroptosis and virus propagation. HCQ: Hydroxychloroquine.